

Naloxone for Overdose Prevention

Prescribing Guidance for Clinical Settings

Summary

Offer to prescribe naloxone to your patients with these risk factors for opioid overdose:

1. High-dose opioid prescription (≥ 100 total morphine milligram equivalents/day)
2. Chronic opioid therapy (≥ 3 months)
3. Opioid* misuse/illicit use, including:
 - a. Current or past history
 - b. In treatment for opioid use disorder (e.g., methadone, buprenorphine, naltrexone, treatment without pharmacotherapy)
 - c. Opioid overdose history
4. Family member or friend of an individual who meets criteria

**Refers to all opioid drug types (e.g., opioid analgesic prescription, heroin) and all routes of administration (e.g., injection drug use, oral, intranasal)*

For patients who meet any of criteria 1–3, additional risk can be conferred by the presence of:

Decreased tolerance after an abstinence period (e.g., incarceration, hospitalization, detoxification).

Opioid use after periods of abstinence, such as after incarceration, substantially increases risk for overdose. Overdose is a leading cause of death after incarceration.^{1,2} The period of abstinence and resulting loss of tolerance associated with incarceration, hospitalization, and detoxification is likely the underlying reason for elevated overdose risk.¹

Concurrent use of central nervous system (CNS) depressants (e.g., benzodiazepines, alcohol):

Concurrent use of opioids and CNS depressants, such as benzodiazepines and alcohol, increase risk for overdose.^{3, 4, 5, 6, 7, 8}

Background

Overdose deaths from opioid analgesics and heroin are a public health crisis in New York City (NYC). In 2013, the majority (77%) of overdose deaths involved an opioid. Between 2000 and 2013, opioid analgesic overdose deaths increased 256%, from 0.9 to 3.2 deaths per 100,000 New Yorkers. Between 2010 and 2013, heroin overdose deaths doubled from 3.1 to 6.2 deaths per 100,000 New Yorkers.⁹ These overdose deaths are preventable, using a comprehensive approach that includes prevention, treatment of opioid use disorder, and raising

public awareness. Because most overdoses are witnessed,¹⁰ a key strategy to prevent opioid overdose deaths is to increase access to naloxone — an antagonist medication that reverses an opioid overdose. In many states, including New York, legislation allows trained laypeople to carry and use naloxone as a first-aid response for an overdose. This strategy is effective. Nationally, since 1996, >150,000 individuals have received naloxone through community-based programs, and >26,000 overdose reversals have been reported.¹¹ A landmark Massa-

Naloxone

for Overdose Prevention

Massachusetts study demonstrated reduced opioid overdose death rates in communities with naloxone distribution programs.¹²

In clinical settings (e.g., primary care practices, emergency departments), naloxone has not been routinely prescribed to patients for overdose prevention, but is more commonly administered by health care professionals for acute, on-site overdose reversals. Prescribing naloxone for overdose prevention to at-risk patients can have a two-fold benefit: the naloxone could be used to reverse an overdose

experienced by the patient, or the patient could use it to reverse an overdose that he/she witnesses. Prescribing naloxone to family members or friends of at-risk individuals can further expand the impact of this life-saving medication.

This guidance can help clinicians prescribe naloxone for overdose prevention; it includes the NYC Department of Health and Mental Hygiene's (DOHMH's) suggested criteria for determining which patients should be offered a naloxone prescription and the evidence for these criteria.

Guidance

DOHMH recommends offering naloxone to patients with the following risk factors for an opioid overdose. These criteria are based on review of the scientific literature, other published naloxone prescribing guidance, and expert opinion.^{13, 14, 15, 16, 17}

- 1. High-dose opioid prescription (≥ 100 total morphine milligram equivalents/day):** Risk of opioid overdose and overdose death increases with higher opioid analgesic dosages.^{18, 19} Taking ≥ 100 morphine milligram equivalents (MME) per day is associated with seven times the risk for overdose death compared with patients taking < 20 MME.¹⁸ DOHMH recommends 100 total daily MME as a threshold for caution and patient reassessment.²⁰ To quickly calculate MME for patients, use OpioidCalc, a free DOHMH app for iOS and Android, specifically developed to assess overdose risk based on total daily MME. If total daily MME is ≥ 100 , consider tapering the dosage and/or trying alternative treatments for pain; offer naloxone for overdose prevention.
- 2. Chronic opioid therapy (≥ 3 months):** Chronic opioid therapy (≥ 3 months) for chronic non-cancer pain is associated with increased risk for overdose. Several factors might explain this observation. Individuals taking chronic opioid therapy might be taking higher dosages, and higher dosages are associated with increased overdose risk.^{18, 19} Additionally, these individuals might be more likely to take long-acting opioids, a formulation which confers a greater risk for overdose.²¹ Risks and benefits of prescribing chronic opioid therapy should be weighed carefully. The most recent reviews on the topic find insufficient evidence that chronic opioid therapy for chronic non-cancer pain improves pain or function.^{22, 23, 24, 25, 26} For patients on chronic opioid therapy, a naloxone prescription can be offered for overdose prevention.

Naloxone

for Overdose Prevention

3. Opioid* misuse/illicit use, including:

**Refers to all opioid drug types (e.g., opioid analgesic prescription, heroin) and all routes of administration (e.g., injection drug use, oral, intranasal)*

a. Current or past history: Current and past history of illicit opioid use²⁷ and/or opioid analgesic misuse are risk factors for overdose.²⁸ All routes of opioid administration can confer overdose risk, although injection drug use is associated with the greatest risk.²⁹ One meta-analysis demonstrated that cohorts with higher injection prevalence had a higher overdose mortality rate (0.83 per 100 person-years) as compared to cohorts with low injection prevalence (0.33 per 100 person-years).³⁰

b. In treatment for opioid use disorder: Several modalities are used to treat opioid use disorder, including pharmacotherapy and treatment without pharmacotherapy. Pharmacotherapy with opioid agonists (methadone and buprenorphine) is the most effective form of treatment; in clinical trials, treatment with opioid agonist therapy is superior to treatment without.^{31, 32} Opioid agonist therapy decreases drug use and mortality.^{31, 32, 33, 34} Another pharmacotherapy option is the opioid antagonist naltrexone. For individuals who have a history of any treatment for opioid use disorder, periods out of treatment are associated with risk of relapse and overdose. In one study, the mortality rate was more than twice as high during out-of-treatment versus in-treatment periods; the risk of death was particularly pronounced in the first month after stopping treatment, with a mortality rate more than eight times higher during this period versus the mortality rate during the stable period of treatment.³³ Offering naloxone to patients receiving any treatment modality can reduce future overdose risk.

c. Opioid overdose history: Previous history of an opioid overdose is a strong predictor of risk for subsequent overdose.^{5, 35, 36} In one survey of drug users, history of previous overdose nearly doubled the risk of experiencing an overdose in the past year.³⁶

4. Family member or friend of an individual who meets criteria: Family members or friends of an individual who meets any of the above criteria can also be offered a naloxone prescription since they may witness an overdose. In a clinical setting, the family member or friend may be the patient or may be accompanying a patient to a visit. New York State Public Health Law provides liability protection for prescribing naloxone to non-patients when the institution or practice is registered as an opioid overdose prevention program. Any hospital or doctor's office can register.*

Naloxone is an important component of a comprehensive approach to reducing opioid overdose, along with effective treatment, judicious opioid prescribing, public awareness, and community initiatives. By offering naloxone for overdose prevention to patients at risk of opioid overdose and their family and friends, New York City health care providers can help prevent overdose mortality. NYC DOHMH offers technical assistance, and educational materials on naloxone for patients and providers.

For more information, contact naloxone@health.nyc.gov.

References

1. Lim S, Seligson AL, Parvez FM, et al. Risks of Drug-Related Death, Suicide, and Homicide During the Immediate Post-Release Period Among People Released from New York City Jails, 2001–2005. *Am J Epidemiol*. 2012; 175(6):519–26.
2. Binswanger IA, Stern MF, Deyo RA, et al. Release from prison—a high risk of death for former inmates. *N Engl J Med*. 2007;356(5):536.
3. Park TW, Saitz R, Ganoczy D, Ilgen MA, Bohnert AS. Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: case-cohort study. *BMJ*. 2015;350:h2698.
4. Seal KH, Kral AH, Gee L, et al. Predictors and Prevention of Nonfatal Overdose Among Street-Recruited Injection Heroin Users in the San Francisco Bay Area, 1998–1999. *Am J Public Health*. 2001;91(11):1842–1846.
5. Coffin PO, Tracy M, Bucciarelli A, Ompad D, Vlahov D, Galea S. Identifying Injection Drug Users at Risk of Nonfatal Overdose. *Acad Emerg Med*. 2007. 14(7): 616–23.
6. Gudín JA, Mogali S, Jones JD, Comer SD. Risks, Management, and Monitoring of Combination Opioid, Benzodiazepines, and/or Alcohol use. *Postgrad Med*. 2013;125(4):115–130.
7. Pawasauskas, J, Stevens B, Youssef R, Kelley M. Predictors of Naloxone Use for Respiratory Depression and Oversedation in Hospitalized Adults. *Am J Health Syst Pharm*. 2014; 71(9): 746–50.
8. Merrall EL, Bird SM, Hutchinson SJ. Mortality of Those who Attended Drug Services in Scotland 1996–2006: record-linkage study. *Int J Drug Policy*. 2012;23(1):24–32.
9. Paone D, Tuazon E, O'Brien DB, Nolan M. Unintentional Drug Poisoning (Overdose) Deaths Involving Opioids in New York City, 2000–2013. *Epi Data Brief*. 2014;50:1–4. Available at: <http://www.nyc.gov/html/doh/downloads/pdf/epi/databrief50.pdf>. Accessed October 15, 2015.
10. Sporer K.A., Strategies for Preventing Heroin Overdose. *BMJ*. 2003; 326(7386): 442–444.
11. Opioid Overdose Prevention Programs Providing Naloxone to Laypersons – United States, 2014. *MMWR Morb Mortal Wkly Rep*. 2015;64(23):631–635.
12. Walley AY, Xuan Z, Hackman HH, et al. Opioid Overdose Rates and Implementation of Overdose Education and Nasal Naloxone Distribution in Massachusetts: Interrupted Time Series Analysis. *BMJ*. 2013;346:f174.
13. Albert S, Brason FW, Sanford CK, Dasgupta N, Graham J, Lovette B. Project Lazarus: Community-Based Overdose Prevention in Rural North Carolina. *Pain Med*. 2011;12 Suppl 2:S77–85.
14. Prescribe to Prevent. Instructions for Healthcare Professionals: Prescribing Naloxone. Available at: http://www.prescribetoprevent.org/wp-content/uploads/2012/11/one-pager_12.pdf. Accessed October 15, 2015.
15. Substance Abuse and Mental Health Services Administration. OpioidOverdose Prevention Toolkit. Available at: http://store.samhsa.gov/shin/content//SMA14-4742/Overdose_Toolkit.pdf. Accessed October 15, 2015.
16. San Francisco Department of Public Health. Naloxone for Opioid Safety: A Provider's Guide to Prescribing Naloxone to Patients Who Use Opioids. Available at: <http://bavareaaetc.org/wp-content/uploads/2015/04/PDF-NaloxoneOpioidSafetyPatients.pdf>. Accessed October 15, 2015.
17. New Mexico Regulation and Licensing Department. Pharmacist Prescriptive Authority of Naloxone Rescue Kit Protocol. Available at: http://www.rld.state.nm.us/uploads/FileLinks/e3740e56e0fe428e991dca5bd25a7519/NRK_Protocol_BOP_Dale_Tinker.pdf. Accessed October 15, 2015.
18. Bohnert AS, Valenstein M, Bair MJ, et al. Association Between Opioid Prescribing Patterns and Opioid Overdose-Related Deaths. *JAMA*. 2011;305(13):1315–1321.
19. Dunn KM, Saunders KW, Rutter CM, et al. Opioid Prescriptions for Chronic Pain and Overdose: A Cohort Study. *Ann Intern Med*. 2010;152(2):85–92.
20. Paone D, Dowell D, Heller D. Preventing Misuse of Prescription Opioid Drugs. *City Health Information*. 2011;30(4):23–30. Available at: <http://www.nyc.gov/html/doh/downloads/pdf/chi/chi30-4.pdf>. Accessed October 15, 2015.
21. Miller M, Barber CW, Leatherman S, et al. Prescription Opioid Duration of Action and the Risk of Unintentional Overdose Among Patients Receiving Opioid Therapy. *JAMA Intern Med*. 2015;175(4):608–615.
22. Manchikanti L, Ailani H, Koyalagunta D, et al. A systemic review of randomized trials of long-term opioid management for chronic non-cancer pain. *Pain Physician* 2011; 14: 91-121.
23. Noble M, Treadwell J R, Treager S J, et al. Long-Term Opioid Management for Chronic Noncancer Pain. *Cochrane Database Syst Rev*. 2010; 1: CD006605.
24. Furlan, AD, Sandoval JA, Malis-Gagnon A, Tunks E. Opioids for Chronic Noncancer Pain: A Meta-Analysis of Effectiveness and Side Effects. *CMAJ*. 2006; 174(11):1589–1594.
25. Martell BA, O'Connor PG, Kerns RD, et al. Systematic Review: Opioid Treatment for Chronic Back Pain: Prevalence, Efficacy, and Association with Addiction. *Ann Intern Med*. 2007; 146(2):116–27.
26. Trescot AM, Glaser SE, Hansen H, Benyamin R, Patel S, Manchikanti L. Effectiveness of Opioids in the Treatment of Chronic Non-Cancer Pain. *Pain Physician*. 2008; 11(2 Suppl):S181–200.
27. Warner-Smith M, Darke S, Lynskey M, Hall W. Heroin Overdose: Causes and Consequences. *Addiction*. 2001; 96(8):1113–1125.
28. Gwira Baumblatt JA, Wiedeman C, Dunn JR, Schaffner W, Paulozzi LJ, Jones TF. High-Risk Use by Patients Prescribed Opioids for Pain and its Role in Overdose Deaths. *JAMA Intern Med*. 2014; 174(5):796–801.
29. Brugal MT, Barrio G, De LF, Regidor E, Royuela L, Suelves JM. Factors Associated with Non-Fatal Heroin Overdose: Assessing the Effect of Frequency and Route of Heroin Administration. *Addiction*. 2002; 97(3):319–27.
30. Degenhardt L, Bucello C, Mathers B, et al. Mortality among Regular or Dependent Users of Heroin and Other Opioids: A Systematic Review and Meta-Analysis of Cohort Studies. *Addiction*. 2011; 106(1): 32–51.
31. Mattick RP, Breen C, Kimber J, Davoli M. Methadone Maintenance Therapy Versus No Opioid Replacement Therapy for Opioid Dependence. *Cochrane Database Syst Rev*. 2009;3: CD002209.
32. Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus Placebo or methadone maintenance for opioid dependence. *Cochrane Database Syst Rev*. 2014;2:CD002207.
33. Cornish R, Macleod J, Strang J, Vickerman P, Hickman M. Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Research Database. *BMJ*. 2010;341:c5475.
34. Fiellin DA, Schottenfeld RS, Cutter CJ, Moore BA, Barry DT, O'Connor PG: Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial *JAMA Intern Med*. 2014;174(12):1947-1954.
35. Darke S, Williamson A, Ross J, Mills KL, Havard A, Teesson M. Patterns of Nonfatal Heroin Overdose Over a 3-Year Period: Findings from the Australian Treatment Outcome Study. *J Urban Health*. 2007; 84(2): 283–91.
36. Grau LE, Green TC, Torban M, et al. Psychosocial and Contextual Correlates of Opioid Overdose Risk Among Drug Users in St. Petersburg, Russia. *Harm Reduct J*. 2009; 6: 17.
37. New York State Public Health Law, Section 3309. Available at: <https://www.health.ny.gov/diseases/aids/consumers/prevention/opioidprevention/docs/regulations.pdf>. Accessed October 15, 2015.